Advisor Group’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$4.41M Buy
56,739
+1,218
+2% +$95.1K 0.03% 452
2019
Q3
$4.07M Sell
55,521
-18,216
-25% -$1.28M 0.03% 478
2019
Q2
$4.54M Buy
73,737
+606
+0.8% +$36.6K 0.03% 425
2019
Q1
$4.66M Buy
73,131
+4,515
+7% +$258K 0.04% 389
2018
Q4
$3.5M Buy
68,616
+16,779
+32% +$849K 0.03% 415
2018
Q3
$3.01M Buy
51,837
+14,466
+39% +$708K 0.03% 495
2018
Q2
$1.81M Buy
37,371
+657
+2% +$30.7K 0.02% 584
2018
Q1
$1.71M Sell
36,714
-3,390
-8% -$147K 0.02% 618
2017
Q4
$1.51M Sell
40,104
-16,443
-29% -$603K 0.02% 678
2017
Q3
$2.06M Sell
56,547
-258
-0.5% -$9.84K 0.03% 492
2017
Q2
$2.24M Buy
56,805
+5,007
+10% +$183K 0.04% 441
2017
Q1
$1.62M Sell
51,798
-9,222
-15% -$289K 0.03% 516
2016
Q4
$1.91M Sell
61,020
-1,914
-3% -$62K 0.04% 439
2016
Q3
$2.53M Buy
62,934
+4,815
+8% +$181K 0.06% 336
2016
Q2
$1.93M Buy
+58,119
New +$1.99M 0.05% 392

Other funds holding EW

Advisor Group's EW Position: Q4 2019 in Review

Advisor Group increased its Edwards Lifesciences (EW) stake by 2.2% in Q4 2019, buying an estimated $95.1K and bringing the position to 56,739 shares worth $4.41M. The position accounts for 0.03% of the portfolio, ranked #452.

Advisor Group first reported a position in EW in Q2 2016 and has held it in 15 quarters since. The position peaked at $4.66M in Q1 2019. 1,093 funds tracked by Wall St. Rank hold EW as of Q4 2019.

  • Advisor Group held 56,739 shares of Edwards Lifesciences worth $4.41M as of Q4 2019.
  • Advisor Group bought 1,218 Edwards Lifesciences shares in Q4 2019, an estimated $95.1K.
  • Edwards Lifesciences made up 0.03% of Advisor Group's portfolio in Q4 2019, its #452 holding.
  • Advisor Group first reported a position in Edwards Lifesciences in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Edwards Lifesciences position peaked at $4.66M in Q1 2019.
  • 1,093 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.